Wedbush maintained an Outperform rating on Sarepta Therapeutic (NASDAQ: SRPT) and lowered its price target to $45.00 (from $60.00). The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Deutsche Bank Cuts Sarepta Therapeutic (SRPT) to Hold, PT $17November 12, 2013 3:54 PM FBR Capital Slashes Sarepta (SRPT) Price Target, But Remains 49% Above Current LevelsNovember 12, 2013 2:45 PM Needham & Company Downgrades Sarepta Therapeutic (SRPT) to HoldNovember 12, 2013 12:46 PM Sarepta (SRPT) Eteplirsen Delay Impacts DCF by $10/sh Each Year - Deutsche BankNovember 12, 2013 9:25 AM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to UnderweightNovember 12, 2013 8:11 AM FDA Considers Sarepta's (SRPT) NDA for Eteplirsen 'Premature'November 12, 2013 7:05 AM